Long-term efficacy of alemtuzumab in polymyositis

Rheumatology (Oxford). 2015 Mar;54(3):560-2. doi: 10.1093/rheumatology/keu484. Epub 2014 Dec 30.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal, Humanized / immunology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antigens, CD / immunology
  • Antigens, Neoplasm / immunology
  • CD52 Antigen
  • Follow-Up Studies
  • Glycoproteins / immunology
  • Humans
  • Male
  • Middle Aged
  • Polymyositis / drug therapy*
  • Time Factors
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Antigens, Neoplasm
  • CD52 Antigen
  • CD52 protein, human
  • Glycoproteins
  • Alemtuzumab